Hi Baz, I am not entirely sure the trial is required to be taken in Japan to enable application and/or approval, different to the US in which this is customary, almost mandatory. Were you exposed to this requirements in any formal document or communication from MSB, the Japanese authorities or any other listed company?
Cell Therapy News/Articles, page-15060
-
- There are more pages in this discussion • 3,369 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.29 |
Change
0.010(0.78%) |
Mkt cap ! $1.467B | |||
| Open | High | Low | Value | Volume |
| $1.29 | $1.31 | $1.27 | $1.068M | 831.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 30 | 26525 | $1.29 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.29 | 81394 | 13 |
View Market Depth
| Last trade - 14.24pm 05/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |